Induction of monocyte antitumor response by human cancer cells transduced with TNF-GFP fusion gene: possible implications for immunotherapy of cancer by Więckiewicz, Jerzy et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 49, No. 3, 2011
pp. 512–520
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0072
www.fhc.viamedica.pl
ORIGINAL STUDY
Correspondence address: J. Więckiewicz,
Department of Clinical Immunology,
Polish-American Institute of Pediatrics,
Jagiellonian University Medical College,
Wielicka Str. 265, 30–663 Krakow, Poland;
tel.: (+ 48 12) 658 24 86, fax: (+ 48 12) 658 17 56;
e-mail: miwiecki@cyf-kr.edu.pl
Induction of monocyte antitumor response by
human cancer cells transduced with TNF-GFP
fusion gene: possible implications for
immunotherapy of cancer
Jerzy Więckiewicz, Bożenna Mytar, Rafał Szatanek,
Kazimierz Węglarczyk, Jarosław Baran
Department of Clinical Immunology, Polish-American Institute of Pediatrics, Jagiellonian University
Medical College, Krakow, Poland
Abstract: This study was undertaken to determine how human pancreatic cancer (HPC-4) cells transduced with
the TNF-GFP fusion gene (TLG) alter the antitumor response of human monocytes in vitro and whether they
could act as an antitumor vaccine. In our model, HPC-4 cells were transduced with retroviral vector harboring
TLG gene and designated as HPC-4TLG. The TLG protein expression was confirmed by Western blot and flow
cytometry analysis. Monocytes were co-cultured with transduced and control HPC-4 cells. The secretion of
TNF, IL-10 and IL-12 was measured by ELISA. The cytotoxicity of monocytes against HPC-4 cells was deter-
mined by MTT test. The results show that the HPC-4TLG cells expressed membrane-bound, intracellular and
secretory TLG protein. When cultured with HPC-4TLG cells, monocytes released a higher amount of TNF, but
IL-10 and IL-12 secretion was inhibited. The pre-exposure of monocytes to HPC-4TLG, but not to HPC-4, cells
did not decrease TNF nor increase IL-10 production, thus not leading to monocyte deactivation. Also, the
antitumor cytotoxicity of monocytes stimulated with HPC-4TLG was not downregulated, which occurred when
non-transduced HPC-4 cells were used. In conclusion, compared to parental HPC-4 cells, TLG gene transduced
HPC-4 cells induced stronger antitumor response of monocytes in vitro and prevented deactivation of mono-
cytes. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 3, 512–520)
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Introduction
A serious problem with the retroviral system of gene
transfer is that it is difficult to maintain a high level
of cloned gene expression following transduction.
Usually, several passages of transduced cells result in
the outgrowth of clones that express much lower lev-
els of the transgene coded protein. The use of the
internal ribosome entry site (IRES) elements rather
than internal promoters could increase the likelihood
of stable expression of the cloned gene of interest.
However, even the use of IRES sequence does not
completely reduce the number of potential mecha-
nisms, both at the transcriptional and post-transcrip-
tional levels, that could affect the transgene expres-
sion [1]. Cloned gene expression also depends on ret-
roviral DNA integration site in the host genome
[2, 3]. Cloning of the gene coding for green fluores-
cent protein (GFP) isolated from the jellyfish Aequo-
rea victoria and its efficient species-independent ex-
pression is a new versatile reporter gene system [4, 5].
Autologous cancer cells used as vaccines to en-
hance antitumor activity have been explored exten-
sively, but their efficiency has proved to be low. There-
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fore, genetically engineered tumor cells transfected
with various cytokines coding genes have been used
[6–8]. However, despite positive effects in murine
experimental tumor models, their clinical efficiency
in human cancer is marginal, with an objective re-
sponse rate of 3.3% [9]. Also, human monocytes that
exert a direct cytotoxic effect on tumor cells, as medi-
ated by radical oxygen intermediates (ROI) and tu-
mor necrosis factor (TNF), upon arrival at the tumor
site form tumor infiltrating macrophages (TIM),
which become polarized to M2 macrophages, thus
strongly reducing their cytotoxic activity [10]. This
occurs due to the tumor cell products, including ex-
tracellular matrix components, IL-10, CSF-1 and oth-
er cytokines. In general, M2 macrophages have poor
antigen presenting capacity, have an IL-12low and
IL-10high phenotype, suppress the inflammatory re-
sponse and Th1 adaptive immunity, and promote an-
giogenesis, tissue remodeling and tumor progression
[10]. Such TIM changes may be responsible, at least
in part, for the inefficiency of tumor vaccines.
We have previously observed that human mono-
cytes stimulated with tumor cells produce TNF,
IL-10 and IL-12 [11]. However, when monocytes were
first pre-exposed to tumor cells, sorted out from co-
culture and then re-stimulated with tumor cells, they
became M2 polarized cells that produced increased
amounts of immunosuppressive IL-10 [11]. There-
fore, we wanted to investigate whether the use of TNF
gene transduced tumor cells might increase their im-
munostimulatory potential for monocytes and prevent
their M2 polarization.
Material and methods
Reagents and antibodies. The oligonucleotides were pur-
chased from TIB Molbiol (Poznan, Poland). Polymerase
chain reaction (PCR) and enhanced avian reverse tran-
scriptase (RT) kits, agarose (for routine use), polybrene
(hexadimethrine bromide), and the antibiotics ampicillin,
neomycin sulfate and tylosin tartrate were from Sigma
Chemical Company (St. Louis, MO, USA). The Pwo DNA
polymerase with the appropriate incubation buffer was ob-
tained from Roche (Basel, Switzerland). Restriction en-
zymes, 1 Kb Plus DNA ladder and T4 DNA ligase were
from Invitrogen (Carlsbad, CA, USA). The jetPEI cationic
polymer transfection reagent was obtained from Qbiogene
(Morgan, Irvine, CA, USA). DMEM and RPMI 1640 me-
dia (both with L-glutamine), and fetal bovine serum (FBS)
were obtained from PAA Laboratories GmbH (Pashing,
Germany). The RetroPack PT67 retrovirus packaging cell
line was purchased from BD Biosciences Clontech (Moun-
tain View, CA, USA). The following antibodies were used:
phycoerythrin (PE)-conjugated monoclonal antibody (mAb)
against human TNF and an appropriate isotype control (BD
Pharmingen, San Diego, CA, USA), Alexa Fluor 594-con-
jugated rabbit polyclonal anti-GFP IgG antibody and rab-
bit anti-FITC Alexa Fluor 594-conjugated polyclonal IgG
antibody (used as an isotype control), purified mouse anti-
-GFP IgG1 mAb (all Molecular Probes, Willow Creek, Eu-
gene, OR, USA), horseradish peroxidase-conjugated goat
anti-mouse IgG (Santa Cruz Biotech, Santa Cruz, CA,
USA), and anti-CD14 PE-labeled mAb (BD Pharmingen).
Reagents for cell fixation and permeabilization (Cytofix/
/Cytoperm and Perm/Wash) were from BD Pharmingen. The
retroviral plasmid vector pMIGR1 [12] was kindly provid-
ed by Dr. Warren S. Pear (University of Pennsylvania, Phil-
adelphia, PA, USA).
Cell cultures. The RetroPack PT67 murine dualtropic cell
line was used for retrovirus packaging and production of
retroviral pMIGR1 and recombinant pMIGR1-TLG
(pTLG) vectors. The established human pancreatic adeno-
carcinoma (HPC-4) cell line [13] was used for transduction
of the TLG fused gene by the recombinant retroviral infec-
tion. The PT67 cells and HPC-4 cells were grown in DMEM
and RPMI 1640 media, respectively, supplemented with the
following antibiotics: 50 μg/ml neomycin, 100 μg/ml ampi-
cillin, 10 μg/ml tylosin, and 10% FBS referred to further as
complete. Both cell lines were incubated at 37°C in a hu-
midified 5% CO2 atmosphere. All cell cultures were rou-
tinely tested for Mycoplasma sp. contamination using
a Mycoplasma PCR ELISA kit (Roche Diagnostics GmbH,
Penzberg, Germany).
Construction of fusion TLG transgene and retroviral
vector preparation. The cDNA encoding human TNF
(26 kDa) was obtained by the RT-PCR method using spe-
cific oligonucleotide primers and the total RNA sample iso-
lated from human blood monocytes stimulated in vitro for
2 h with LPS (1 μg/ml). The synthesis of the first strand cDNA
was carried out with enhanced avian RT and anchored oli-
go-dT primers according to the manufacturer’s instructions.
The PCR amplification of the first strand of TNF-cDNA
was performed using the Pwo DNA polymerase and the fol-
lowing primers: BglFtnf sense 5’-GCGCAGATCTATGAG-
CACTGAAAGCATGAT-3’ which provided BglII site (bold-
ed) and XhoRtnf antisense 5’-CATATATCTCGAG-
CAGGGCAATGATCCCAA-3’ which provided XhoI site
(bolded). The TNF-cDNA was cleaved with BglII and XhoI
restriction enzymes and ligated to the BglII-XhoI linear-
ized vector pMIGR1 to give the recombinant pMIGR1-TNF
plasmid. The LIN23-cDNA sequence coding for a linker of
23 amino acid residues was synthesized in a PCR reaction
using 82-mer oligonucleotide 5’-ATATACTCGAG-
[(GGC)4TCT]4GCCATGGTAT-3’ as the template and the
primers: LinSXho sense 5’-ATATACTCGAGGGCGGCG-
GC-3’ which provided XhoI site (bolded)and LinRNco an-
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tisense 5’-GATACCATGGCAGAGCCGCC-3’ which pro-
vided NcoI site (bolded). The LIN23-cDNA was cleaved
with XhoI and NcoI enzymes, cloned and replaced in the
pMIGR1-TNF plasmid at the XhoI-NcoI IRES fragment
to give the final vector designated as pTLG which contained
TLG transgene coding for the TLG fusion protein.
Production of retroviral particles. The pTLG plasmid
transfer was performed using the jetPEI transfection reagent
according to the manufacturer’s protocol. Transfected PT67
cells expressing the TLG protein were isolated by sorting
with the use of FACS Vantage with DiVa option (BD Bio-
sciences Immunocytometry Systems, San Jose, CA, USA)
equipped with an aerosol protection system (Flexoduct In-
ternational, Greve, Denmark) using DiVa software. The ion
laser Innova Enterprise II (Coherent, Santa Clara, CA,
USA) operating at 488 nm was used as a light source. Sort-
ed PT67 cells were propagated in complete DMEM medi-
um until cell culture reached confluency and sorted again.
Double-sorted PT67 cells producing retrovirus were plated
at 60–80% confluency in the desired number of culture ves-
sels. The supernatants were harvested at 24 h intervals until
cells were no longer viable. The supernatants were collect-
ed, spun at 500 × g for 10 min and stored at –70°C until use.
Transduction of human HPC-4 cells. The target HPC-4
cells were cultured in complete RPMI 1640 medium for 24 h
at 1–2 × 105 per 60-mm Petri dishes (Becton Dickinson
Labware, Franklin Lakes, NJ, USA). Then the medium was
replaced with 2.5 ml of thawed supernatant from transfect-
ed PT67 cells diluted 1:1 with fresh complete RPMI 1640
medium supplemented with polybrene (final concentra-
tion 5 μg/ml). The retroviral infection of the HPC-4 cells
was performed three times sequentially at 12 h intervals.
Then the HPC-4 cells were cultured for 48 h and sorted
two times sequentially on the basis of the TLG protein
fluorescence as described above. The purity of the sorted
TLG positive cells (HPC-4TLG) was checked by flow cy-
tometry re-analysis. As the control, HPC-4 cells transduced
with the original pMIGR1 retroviral vector and designat-
ed as HPC-4GFP were used.
Western blot analysis of TLG fusion protein expression.
HPC-4 cells and their genetically modified clones, HPC-
4GFP and HPC-4TLG cells were lysed in M-PER protein ex-
traction reagent (Pierce Biotechnol, Rochford, IL, USA)
containing protease and phosphatase inhibitors (Sigma).
The extracted proteins (30 μg) were loaded on 4% loading
gel, separated in 12% SDS gel and transferred to the poly-
vinylidene fluoride membrane (Immune-blot PVDF, 2 μm,
BioRad, Hercules, CA, USA). GFP was detected with anti-
-GFP mAb IgG1 (Molecular Probes) and with horseradish
peroxidase-conjugated goat anti-mouse IgG (Santa Cruz
Biotech, Santa Cruz, CA, USA), as a secondary antibody.
The membranes were developed with the SuperSignal West
Pico Chemiluminescent Substrate (Pierce), dried and sub-
sequently exposed to HyperFilm (Amersham Life Science,
Little Chalfont, UK).
Intracellular detection of GFP and TLG fusion protein.
Intracellular staining for the detection of GFP and TLG
fusion protein was performed after cell fixation and perme-
abilization, as previously described [14]. Briefly, HPC-4 cells
and their genetically modified clones were fixed and per-
meabilized with Cytofix/Cytoperm solution (BD Pharmin-
gen) for 20 min at 4°C. Then, the cells were washed twice in
Perm/Wash solution (BD Pharmingen) and pelleted cells
were stained (30 min at 4°C) for intracellular detection of
GFP and TLG fusion protein using Alexa Fluor 594-conju-
gated anti-GFP rabbit IgG and PE-conjugated mAb against
human TNF. Appropriate matched isotype controls were
used in parallel.
Flow cytometry analysis. Samples were analyzed in a FACS
Canto flow cytometer (BD Biosciences) using DiVa soft-
ware. The list mode data of 50,000 events from HPC-4 cells
in a ‘live gate’ mode was acquired. The cells were gated ac-
cording to FSC and SSC parameters. Intracellular GFP and
TLG proteins were determined by green fluorescence mea-
surement in channel FL1. Intracellular and membrane-bound
TLG fusion proteins were also detected according to FL4
(Alexa Fluor 594-conjugated anti-GFP rabbit IgG) and FL2
(PE-conjugated mAb against human TNF) emission.
Isolation of cell populations. Human monocytes were sep-
arated from peripheral blood mononuclear cells of healthy
donors by counter-flow elutriation, using a JE-6B elutria-
tion system (Beckman Instruments, Palo Alto, CA, USA),
as previously described [15]. They were 90–98% pure, as
judged by staining with anti-CD14 mAb. Monocytes were
suspended in RPMI 1640 medium with 5% FBS at the con-
centration of 1 × 106 cells/ml for in vitro cultures. In some
experiments, monocytes isolated from a co-culture with
parental or transduced HPC-4 cells (pre-exposure) at the
ratio 1:0.3 for 4 h, were used. For this purpose, after stain-
ing with PE-labeled anti-CD14 (BD Biosciences) mAb,
CD14+ cells were isolated by FACS sorting (FACS Vantage
with DiVa option, Becton Dickinson Immunocytometry
Systems). The purity of the sorted cells was checked by flow
cytometry, and exceeded 95%. As control, CD14+ cells were
sorted out from monocytes cultured in medium alone (‘dum-
my sorting’).
Determination of cytokine release. HPC-4, HPC-4GFP and
HPC-4TLG cells (1 × 10
5/well) were incubated in RPMI 1640
medium with 5% FBS for 18 h in flat-bottom wells microti-
ter plates (Nunc, Roskilde, Denmark). Then, the superna-
tants were harvested and the concentration of TNF was
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measured by ELISA. Also, monocytes (1 × 105/well) were
incubated either in the medium alone or with parental HPC-4,
or HPC-4GFP or HPC-4TLG (3 × 10
4/well) for 18 h (as above)
and the level of TNF, IL-10 and IL-12 was determined. In
some experiments, isolated CD14+ cells were cultured in
the medium alone or with parental HPC-4 or their geneti-
cally modified clones (as above), and the level of cytokines
was measured. All the cytokine level measurements were
performed in duplicates using commercial ELISA kits (BD
Pharmingen).
Cytotoxicity assay. Monocytes (5 × 104/well) were cultured
for 6 h in the medium alone or with g-irradiated (2500 cGy)
HPC-4 or HPC-4GFP or HPC-4TLG cells (5 × 10
3/well), and
then non-irradiated HPC-4 cells (2 × 104/well) were added
and cultured for a further 18 h. The culture medium was
removed and 100 μl of MTT (3-(4,5-dimethylthiazol-2-yl)-
-2,5-diphenyltetrazolium bromide) (2 mg/ml, Sigma) dye so-
lution was added for the last 2 h. Cell proliferation was as-
sessed by the reduction of MTT. The data was expressed as
the percentage of cytotoxicity calculated, as previously de-
scribed [16].
Statistical analysis. The one-way analysis of variance ANO-
VA and post hoc Tukey test was used to calculate the statis-
tical significance between individual treatments. Differenc-
es were considered as significant at p < 0.05.
Results
TLG-transduced tumor cells
The cDNA coding for human 26 kDa TNF was fused
to the 5’ end of the cDNA coding enhanced version
of the GFP protein. The short sequence of cDNA —
CTC GAG [(GGC)4 TCT]4 GCC — coding for a small
flexible linker was inserted between TNF-cDNA and
GFP-cDNA to obtain fused gene designated as TLG.
This gene was cloned in the retroviral vector pMI-
GR1 [12] to obtain the final retroviral vector pTLG
(Figure 1). The pTLG expression vector was used as
a delivery system to HPC-4 tumor cells. The effec-
tiveness of transduction ranged from 0.1% to 0.5%.
Transduced HPC-4TLG cells following FACS sorting,
yielded 1–10% TLG+ cells. After propagation of these
selected cells and re-sorting, the purity of TLG+ cells
exceeded 95% (Figure 2). In parallel, the HPC-4GFP
cells mock-transduced with the original empty pMI-
GR1 vector were also more than 95% GFP+ (not
shown). The HPC-4TLG cells demonstrated stable flu-
orescence of the TLG fusion protein, even after 30
days of maintenance in vitro in cultures with nonse-
lective medium. The mean fluorescence intensity
(MFI) of the HPC-4TLG cells was about 4,000 versus
200 MFI for the nontransduced cells. The percent-
age of TLG positive cells decreased to about 60–70%
Figure 1. Linear scheme of the retroviral vector pTLG (B)
construction using the parental pMIGR1 vector (A).
The retroviral fragment of the vectors contain the following
sequences: TNF — human pre-TNFa-cDNA (719 bp);
LTR — retroviral Long Terminal Repeats; y2 — sequence
necessary for packaging viral RNA into virus capsids;
IRES — sequence Internal Rybosomal Entry Site from
EMCV virus; GFP — gene coding enhanced form of Green
Fluorescent Protein; LIN23 – sequence coding for linker
[(Gly)4Ser]4 Ala. The schemes of pMIGR1 and pTLG
vectors do not show the prokaryotic fragment of the entire
plasmid. The schemes are not drawn to scale
Figure 2. TLG positive HPC-4 cells detected by flow cytometry. Left dot plot — three days after transduction;
middle — three days after propagation of FACS sorted initially TLG positive cells; right — three days after propagation
of FACS re-sorted TLG+ cells. Data from one representative experiment out of five performed is shown.
The numbers show percentage of TLG positive cells in a region set according to green fluorescence (FL1)
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by day 30 post-transduction. However, the subsequent
FACS sorting allowed selection of stable transductants
expressing the TLG fusion protein for an additional
2–3 months in culture.
TNF expression in the TLG-transduced
tumor cells
The amount of TNF secreted from HPC-4TLG cells was
2,428 ± 466 pg/ml (mean ± SEM), while mock-trans-
duced HPC-4GFP and parental HPC-4 cells did not
produce TNF (Figure 3). No IL-6, IL-10, MIP1a or
RANTES were found in the supernatants of HPC-
-4TLG cells (data not shown).
As membrane bound TNF is regarded as impor-
tant in the cellular interactions [17], in the next step
we analyzed whether synthesized TLG fusion pro-
tein was expressed as the membrane-bound form.
For this purpose, transduced HPC-4TLG cells were
stained with anti-TNF PE-conjugated mAb. How-
ever, taking into consideration significant spillover
of green fluorescence from enhanced GFP into PE
channel (data not shown), we took an advantage
from anti-GFP antibodies conjugated with Alexa
Fluor 594, the dye which did not interfere with PE
emission spectrum. Anti-GFP antibodies were used
in parallel with anti-TNF mAb for cell staining. Af-
ter staining, the cells were analyzed by flow cytome-
try according to FL4 (anti-GFP) and FL2 (anti-TNF)
fluorescence. In comparison to control HPC-4 and
HPC-4GFP cells, two-color flow cytometry analysis of
HPC-4TLG cells showed that 30.9% of cells stained
with anti-TNF mAb, 31.3% were GFP+ while 19.5%
were both TNF and GFP positive (Figure 4). Intra-
cellular staining of HPC-4TLG cells with anti-TNF and
anti-GFP Abs showed 40.6% TNF+ and GFP+ 95.3%
cells (Figure 5A). Anti-GFP Ab stained 84.3% of
HPC-4GFP cells and none of parental HPC-4 cells.
Figure 4. Expression of membrane-bound TLG fusion protein by HPC-4, HPC-4GFP and HPC-4TLG cells. Cells were
stained with PE-conjugated anti-TNF mAb and anti-GFP Alexa Fluor-594 conjugated Ab, and were analyzed by flow
cytometry according to FL2 (PE) vs. FL4 (Alexa Fluor-594) fluorescence. Representative data from one out of four
experiments performed is shown
Figure 3. TNF secretion by: (A) HPC-4, (B) HPC-4GFP
and (C) HPC-4TLG cells. Data is based on five independent
experiments, two replicates per treatment, and expressed
as pg/ml/1 × 105 cells/18 hours. Mean values ± SEM are
shown; HPC-4TLG vs. HPC-4 and HPC-4GFP; p < 0.001
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The intracellular co-expression of TNF and GFP in
HPC-4TLG cells was confirmed by Western blot anal-
ysis of lysates from TLG transduced cancer cells
(Figure 5B).
Induction of cytokines in monocytes stimulated
with TLG-transduced tumor cells
Monocytes were cultured for 18 h with HPC-4TLG or
HPC-4GFP or parental HPC-4 cells to test whether they
stimulated differently TNF, IL-10 and IL-12 produc-
tion in monocytes. In comparison to parental HPC-4,
HPC-4TLG cells induced significantly higher release of
TNF, while the induction of IL-10 was significantly
lower, and no IL-12 was detected (Figure 6). Inter-
estingly, monocytes stimulated with mock-transduced
HPC-4GFP cells produced significantly less TNF and
no IL-10 or IL-12 compared to those stimulated with
parental HPC-4 cells.
Figure 5. Expression of intracellular TLG fusion protein by: (A) flow cytometry and (B) Western blot analysis.
A. HPC-4, HPC-4GFP and HPC-4TLG cells. Cells were fixed and after permeabilization were stained for intracellular expression of
TNF and GFP, as in Figure 4. Cells were analyzed by two-color flow cytometry according to FL2 vs. FL4 fluorescence. Repre-
sentative data from one out of four experiments performed is shown. B. Western blot analysis of intracellular expression and
localization of GFP protein (27 kDa) and TLG fusion protein (53 kDa) in the lysates of transduced HPC-4GFP and HPC-4TLG cells
using anti-GFP IgG1 mAb as the primary and horseradish peroxidase-conjugated goat anti-mouse IgG as the secondary Abs
Figure 6. Secretion of TNF, IL-10 and IL-12 by monocytes
cultured in the medium (Med) or with: (A) HPC-4 or (B)
HPC-4GFP or (C) HPC-4TLG cells for 18 h. No cytokines were
released by tumor cells except HPC-4TLG, which secreted
900 ± 180 pg/ml of TNF/3 × 104 cells/ml (not shown).
The results of five different experiments, two replicates per
treatment (mean ± SEM) are shown; for TNF: HPC-4 vs.
HPC-4TLG p < 0.01, HPC-4GFP vs. HPC-4TLG p < 0.01; for
IL-10: HPC-4 vs. HPC-4TLG p < 0.01, HPC-4 vs. HPC-4GFP
p < 0.001; for IL-12: HPC-4 vs. HPC-4GFP and HPC-4TLG p < 0.01
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Transduced tumor cells prevent
deactivation of monocytes
We have previously shown that short pre-exposure of
monocytes to tumor cells deactivated them, as evi-
denced by decreased TNF and enhanced IL-10 pro-
duction [11]. In order to check whether transduced
HPC-4 cells act similarly, monocytes were cultured
for 4 h with parental HPC-4 or transduced HPC-4GFP
or HPC-4TLG cells. CD14
+ cells were then isolated by
FACS sorting and stimulated with HPC-4 cells for 18 h.
Figure 7 shows that pre-exposure of monocytes to pa-
rental HPC-4 cells inhibited TNF and IL-12 and en-
hanced IL-10 production. In contrast, HPC-4TLG cells
neither caused inhibition of TNF and IL-12 synthesis
nor enhancement of IL-10 production. Pre-exposure
of monocytes to mock-transduced HPC-4GFP cells
caused similar production of TNF, IL-10 and IL-12
as those pre-exposed to parental cells.
Cytotoxicity of monocytes pre-exposed to
g-irradiated HPC-4TLG
Monocytes/macrophages possess significant sponta-
neous cytotoxicity against tumor cells [16], which is
decreased by the pre-exposure to tumor cells. This
decrease is a part of the monocytes’ deactivation. To
check whether HPC-4TLG cells may also prevent inhi-
bition of cytotoxicity, monocytes were preincubated
with g-irradiated HPC-4 or HPC-4GFP, or HPC-4TLG
cells, and cytotoxicity against HPC-4 tumor cells was
measured. As expected, monocytes pre-exposed to
HPC-4 or HPC-4GFP cells demonstrated lowered cy-
totoxicity (Figure 8). In contrast, there was no inhibi-
tion of cytotoxicity when monocytes were pre-exposed
to HPC-4TLG cells.
Figure 7. Secretion of TNF, IL-10 and IL-12 by monocytes
pre-exposed to tumor cells. Monocytes were pre-incubated
in the medium alone (Med) or with (A) HPC-4 or (B)
HPC-4GFP or (C) HPC-4TLG cells for 4 h. Then CD14
+
monocytes were isolated by FACS sorting and stimulated
with HPC-4 cells. The results of four different experiments,
two replicates per treatment (mean ± SEM) are shown;
HPC-4 vs. HPC-4TLG p < 0.05, HPC-4GFP vs. HPC-4TLG
p < 0.05 (for TNF and IL-10 only)
Figure 8. Cytotoxic activity against HPC-4 cells of monocy-
tes incubated in the medium alone (Med — control), pre-
exposed to g-irradiated: (A) HPC-4 or (B) HPC-4GFP or (C)
HPC-4TLG cells. Cell proliferation was assessed by MTT
reduction. Data (mean ± SEM) based on four experi-
ments, two replicates per treatment, expressed as the
percentage of cytotoxicity is shown; HPC-4 vs. HPC-4TLG
p < 0.05; HPC-4GFP vs. HPC-4TLG p < 0.05
Discussion
For a successful cancer gene therapy, it is fundamen-
tal to obtain as many cells transduced with the thera-
peutic gene as possible. Thus, knowing the actual gene
transfer rate is critical. The GFP has made a break-
through in gene transfer technology. It is a small pro-
tein that fits most of the currently used vectors and
can be fused with other proteins to yield therapeutic
fusion proteins [5, 18, 19]. The use of GFP fusion pro-
teins provides enhanced sensitivity and resolution
compared to antibody staining techniques and per-
mits kinetic studies of a fusion protein localization
[4, 20]. The construction of the fusion protein often
requires the linking of two proteins or protein domains
by an appropriate polypeptide linker. Many studies
have suggested that the flexibility and hydrophilicity
of the linker were very important in preventing the dis-
turbance of the functions of both domains [21, 22].
In the present study, the TLG fusion gene was
constructed by joining the TNF-cDNA and enhanced
GFP-cDNA with the LIN23-DNA, coding for a short,
flexible and hydrophilic linker Leu Glu [(Gly)4 Ser]4
Ala, which allowed retention of GFP and TNF ex-
pression. The retroviral vector pTLG carrying the
TLG fusion gene was used for transduction of HPC-4
cells. The TLG gene transduced cells exhibited un-
changed morphology and proliferation during in vit-
ro culture for more than six months as compared to
the parental nontransduced cells. The TLG gene
transduced cells secreted a substantial amount of TNF,
the presence of which was observed on their mem-
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brane and intracellularly. One could argue that only
a part of the GFP+ cells express TNF at the same time
(Figures 4 and 5). In the preliminary set of experi-
ments, we compared membrane and intracellular ex-
pression of TNF in HPC-4TLG cells without anti-GFP
staining. Under such conditions, the amount of dou-
ble positive cells was only around 50–60% of GFP+
cells (for both membrane and intracellular staining
— data not shown). Such a relatively small amount
of double positive cells could be a result of a spillover
of green fluorescence from enhanced GFP to the PE
channel, which could not be fully compensated dur-
ing FACS analysis. To resolve this issue, we changed
our detection method and introduced staining with
anti-GFP Ab conjugated with Alexa Fluor 594, a dye
which does not interfere with PE. This approach, how-
ever, did not improve the expression ratio, neither in
surface nor intracellular staining. Thus, the relatively
low number of double positive HPC-4TLG cells during
membrane staining was probably due to secretion of
TNF, cleaved rapidly from the TLG protein, to the
medium. In the case of intracellular staining, the high
amount of TLG present in the cytoplasm is probably
neither properly folded nor fully accessible for both
antibodies used for FACS analysis. Such an explana-
tion is supported by Western blot analysis of HPC-
-4TLG cell lysates showing intracellular expression of the
fusion protein (Figure 5B). It shows that there is also
a band of free GFP present, which was probably left
after the cleavage of TNF from TLG and its secre-
tion. However, the exact trafficking and processing
of the TLG fusion protein in transduced HPC-4 can-
cer cells has not been investigated in the present pa-
per, and should be addressed in our future studies.
It has been previously shown that monocytes re-
spond to tumor, but not normal, cells by producing
several toxic mediators: TNF, ROI, radical nitrogen
intermediates (RNI) and increased cytotoxicity [16,
23, 24]. On the other hand, clinicopathological evi-
dence suggests that TIM, of which monocytes are
precursors, may enhance the growth of some tumors
[25]. Our previous data showed that although the first
contact of monocytes with tumor cells induces anti-
tumor activity, secondary contact leads to their deac-
tivation (diminished TNF, IL-12 and ROI production,
decreased cytotoxicity and enhanced IL-10 produc-
tion), i.e. they became M2 polarized monocytes [25].
In the present experiments, we have investigated
how the contact with tumor cells expressing TNF
changes the activity of monocytes. In comparison to
parental cells, HPC-4TLG cells induced higher produc-
tion of TNF by monocytes and lower IL-10. Contrary
to what could be expected, we found that HPC-4GFP
cells, compared to parental HPC-4 cells, caused a
decrease in the secretion of all tested cytokines by
monocytes. Although we have no formal proof, this
phenomenon may be due to more accelerated apop-
tosis of GFP transduced cells [26], which are rapidly
phagocytosed by monocytes during their co-culture.
Phagocytosis of apoptotic cells by monocytes, as evi-
denced by us and others, does not lead to secretion
of TNF, IL-10 or IL-12. The only cytokine released
by monocytes/macrophages during phagocytosis of
apoptotic cells is TGFb, which was not analyzed in
our study. Another concern may arise when analyz-
ing TNF secretion in the co-culture of monocytes and
HPC-4TLG cells. In this case, the question is whether
the TNF release comes from the transduced cells
(GFP-TNF), or from the monocytes alone. Indeed,
in this situation both cell populations may be a source
of TNF; however, as indicated in the legend of Fig-
ure 6, the amount of TNF secreted by HPC-4TLG cells
(900 ± 180 pg/ml of TNF/3 × 104 cells/ml) is far less
compared to the level secreted by monocytes, thus
having little effect on the total level of this cytokine
in the co-culture supernatants.
The CD14+ monocytes sorted out from the co-cul-
ture with HPC-4 cells and restimulated with HPC-4,
showed decreased TNF and IL-12 production. How-
ever, CD14+ cells isolated from the co-culture with
HPC-4TLG produced a higher level of TNF and IL-12
and a diminished level of IL-10. This may suggest that,
in the presence of TNF on the cell surface of HPC-
-4TLG or released by them, no deactivation of mono-
cytes occurred. The observation that cytotoxic activi-
ty of monocytes pre-exposed to HPC-4TLG cells was
not diminished also confirmed this suggestion.
The ability of TNF to activate monocytes/mac-
rophages has been widely reported [17, 27, 28]. Acti-
vated monocytes/macrophages produce several toxic
mediators such as RNI, ROI and TNF, which are
probably directly involved in tumor cell killing in vit-
ro. TNF may be also involved in indirect tumor cell
killing by inducing RNI and ROI [29]. The inhibition
of tumor growth after transduction of cancer cells with
DNA construct coding for TNF has been observed,
although different experimental models and divergent
results concerning the activity of membrane-bound
vs. secreted TNF have been reported [6, 17, 30]. It
has been suggested that in immunocompetent mice,
tumor regression was T cell-dependent [6, 30], while
in immunodeficient mice the effect was macrophage-
-dependent [6]. Membrane bound TNF is regarded
as important in the cellular interactions, e.g. with mu-
rine macrophages [17]. In keeping with this, HPC-4TLG
cells effectively stimulated human monocytes for TNF
release, while decreasing IL-10 and IL-12 secretion.
In summary, the present data indicates that hu-
man cancer cells transduced with TNF-cDNA release
TNF and express its membrane-bound form. These
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cells induced a higher TNF production by monocytes,
and prevented their deactivation, thus giving a ratio-
nale for tumor cell based immunotherapy of cancer.
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